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Abstract
Bacterial infections caused by Shigella flexneri, Salmonella typhimurium and Burkholderia
pseudomallei are currently difficult to prevent due to the lack of a licensed vaccine. Here we
present formulation and immunogenicity studies for the three type III secretion system (TTSS)
needle proteins MxiHΔ5, PrgIΔ5 and BsaLΔ5 (each truncated by five residues at its C terminus) as
potential candidates for vaccine development. These antigens are found to be thermally stabilized
by the presence of carbohydrates and polyols. Additionally, all adsorb readily to aluminum
hydroxide apparently through a combination of hydrogen bonds and/or Van der Waals forces. The
interaction of these proteins with the aluminum-based adjuvant changes with time to resulting in
varying degrees of irreversible binding. Peptide maps of desorbed protein, however, suggest that
chemical changes are not responsible for this irreversible association. The ability of MxiHΔ5 and
PrgIΔ5 to elicit strong humoral immune responses was tested in a murine model. When
administered intramuscularly as monomers, the needle components exhibited dose dependent
immunogenic behavior. The polymerized version of MxiH was exceptionally immunogenic even
at low doses. The responses of both monomeric and polymerized forms were boosted by
adsorption to an aluminum salt adjuvant.
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INTRODUCTION
Shigella flexneri, Salmonella typhimurium and Burkholderia pseudomallei are three
pathogens responsible for an extensive number of potentially preventable diseases. For
example, Shigella is one of the leading causes of infant mortality in developing countries,
and is responsible for the infection of more than 165 million people each year worldwide.1
Salmonella is best known for its high-profile outbreaks in the developed world and is
associated worldwide with more than 200 million cases every year.2–4 Burkholderia is
endemic to tropical regions, and is listed as a Category B Bioterrorism Agent by the CDC
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due to the severity of acute disease , the potential for aerosol delivery and worldwide
availability.5 In all of these cases, there are no licensed vaccines for prevention of infection
by these pathogens, which are also becoming increasingly resistance to antibiotic
treatment.6–9 The need for vaccine development in this area is widely recognized and the
work presented here targets this effort.
S. flexneri, S. typhimurium and B. pseudomallei each relies upon a type three secretion
system (TTSS) as an essential virulence component. The type III secretion apparatus
(TTSA) is appropriately referred to as a molecular ‘injectisome’ and is composed of more
than 20 proteins which assemble to form basal and extracellular components.10 This
macromolecular conduit allows the bacteria direct physical contact with a host cell and is
responsible for the transport of effector proteins from the bacterial cytoplasm directly into
target cells where they subvert normal cellular functions.11–13 The surface exposed ‘needle’
portion of the structure is composed of a defined number of monomeric subunits
polymerized into a hollow helical array with an inner pore diameter of approximately 1.5 to
3.0 nm.14–17 This appendage is required for virulence and is intimately involved in the
initial stages of an infection10,18. Therefore we have explored the use of these surface
exposed proteins as potential vaccine antigens.
The vaccine antigens studied here are the monomeric subunits of the oligomerized needle
appendage from each bacterial system. These small (~10 kDa), acidic (pI <5) proteins are
characterized by distinct patches of both positive and negative surface charge, which
probably contribute to their intrinsic polymerization properties.19 When some of these
proteins are expressed recombinantly, their propensity to oligomerize results in a viscous
solution of highly associated products; however, it is possible to prepare them as soluble
monomers when five residues are deleted from the C terminus.20 The resulting recombinant
proteins, MxiHΔ5, PrgIΔ5 and BsaLΔ5, from the gram-negative bacteria S. flexneri, S.
typhimurium and B. pseudomallei, respectively, have been shown to retain native
structure.20
Previously, we characterized the solution stability of these mutant monomeric needle
antigens, and found them to be pH sensitive, thermally-labile proteins with reversible
transitions and molten globule-like behavior in the physiological temperature range.21 Here
we describe formulation studies of these vaccine candidates accompanied by examination of
the immunogenicity of MxiH Δ5 and PrgI Δ5 in a murine model. BsaL Δ5 was not studied
due to material limitations. We have also formulated a recombinant polymeric needle
construct of MxiH which mimics the actual polymerized TTSS needle structure. In many
cases, antigens with repeating epitopes display greater immunogenicity than those
possessing only a single recognition site. Increased antigen size (as occurs upon
polymerization) has also been shown to likewise increase immunogenicity.22 It should be
emphasized that the intention of this work is not to propose a final clinical formulation, but
rather to examine aspects of potential future formulations which may be useful for further
development of these and related vaccines based on the needle proteins.
MATERIALS AND METHODS
Materials
C-terminal truncated proteins were expressed in E. coli with a C-terminal His6 tag as
described previously.17,20 Affinity purification was performed using nickel chelation
chemistry, and the samples were stored in 20mM isotonic pH 6 citrate phosphate buffer and
stored at −80 °C until use. For immunogenicity studies, MxiH was also expressed in its full
length form, resulting in largely polymerized material referred to as ‘Needle’ hereafter (data
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not shown). Alhydrogel® (2%) and Adjuphos® were acquired from E.M. Sergeant Pulp and
Co., Inc. (Clifton, NJ).
Screening for Excipients
Potential excipients were screened for stabilizing effects using far-UV circular dichroism
spectroscopy. Secondary structure was used as the stability indicating parameter in this case
because of the lack of other useable temperature sensitive signals (i.e., Trp fluorescence,
static light scattering, etc.) exhibited by these proteins.21 Thermal melts were conducted
using a Jasco J-720 spectropolarimeter equipped with a six position sample holder and a
Peltier temperature control device (Easton, MD). Initially, individual far-UV CD spectra
were recorded for each of 6 samples at 10 °C from 260 to 190 nm in a 0.1 cm path length
cell. The cell holder temperature was then increased from 10 to 85 °C in increments of 0.5
°C. At each temperature step the cell holder was incubated for 5 min to ensure thermal
equilibration of the samples before a spectrum was obtained. For each thermal melt, a
control protein sample containing 0.25 mg/mL protein in 20mM isotonic citrate phosphate
buffer at pH 6.0 was run simultaneously with 5 samples containing test compounds at the
indicated concentrations. Spectra of the compounds alone were also collected and subtracted
from the protein spectra when necessary. Using the instrument software, the resulting data
were converted to molar ellipticity as a function of temperature. Midpoints of thermal
transitions (Tms) were determined using Microcal Origin® sigmoidal fit graphing tools.
Adsorption Isotherms
Protein was dialyzed into isotonic 10 mM histidine buffer at pH 6 overnight at 4 °C using
3,500 MWCO Slide-A-Lyzer Dialysis Cassettes (Thermo Scientific, Rockford, IL). Upon
completion, the protein concentration was determined by UV absorbance spectroscopy using
an Agilent 8453 UV/Vis spectrophotometer equipped with a diode array detector (Agilent
Technologies, Santa Clara, CA). Extinction coefficients of 9,970, 11,460, and 12,950 M−1
cm−1 at 280 nm were used for MxiH Δ5, PrgI Δ5 and BsaL Δ5, respectively.21 Protein was
then adsorbed to Alhydrogel by combining a pre-determined volume of Alhydrogel stock,
protein stock and histidine buffer to produce a range of protein concentrations (0–1.25 mg/
mL) and a constant aluminum concentration (0.5 mg/mL), and allowing it to rotate end-
over-end at 4 °C for 1 hour. Samples were then centrifuged at 14,000× g for 30 sec, and the
resulting supernatant was removed and assayed for protein content by UV absorbance
spectroscopy. The amount of protein adsorbed was determined by subtracting the amount
found in the supernatant from the original amount added.
Adsorption Mechanism
‘Elution’ solutions (see Table 1) were prepared in 20mM isotonic pH 6 histidine buffer
using ACS grade reagents and were not pH adjusted. The adsorption protocol described
above was used to prepare several 1.5 mL samples containing 0.2 mg/mL protein per 0.5
mg/mL aluminum, a ratio at which > 95% of the protein was found to be adsorbed. The
samples were then centrifuged for 2 min at 3,000× g to pellet the aluminum-protein
complex, and the resulting supernatant was removed. A control sample was prepared by
adding 1 mL of isotonic 10 mM histidine buffer at pH 6 to an aluminum-protein pellet. In
the same way, 1 mL of an ‘elution’ solution was added to each tube containing a centrifuged
aluminum-protein pellet (The pellets were redispersed in the elution solution by flicking the
sides of the tubes and centrifuging for 5 sec). All vials were then rotated end-over-end at 4
°C for 48 hours. The samples were then once again centrifuged, and the supernatant of each
evaluated for protein content.
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Capillary liquid chromatography-mass spectrometry analysis and protein mapping
A 0.1 mg/mL trypsin solution was prepared by dissolving 5.2 mg of trypsin in 52 mL of
0.05 M ammonium bicarbonate buffer at pH 6.6. Protein was exposed to the trypsin solution
at a 1:200 concentration ratio, and incubated at 37 °C for > 1 hour to permit adequate
digestion. Samples were introduced into an LTQ-FT Ultra Hybrid Mass Spectrometer
(ThermoFinnigan) via capillary liquid chromatography as described.23 A data-dependant
acquisition method was used for setting up the experiments. The five most intensive
precursor ions in a survey MS1 mass spectrum acquired in the Fourier transform-ion
cyclotron resonance over a mass range of 300–2000 m/z were selected and sequentially
fragmented for MS2 analysis in the linear ion trap by collision-induced dissociation.
Experimental raw files were processed by TurboSequest batch search using BioWorks 3.2
software. All text files generated by BioWorks 3.2 for every MS2 fragmentation spectrum
were combined within each experiment using an in-house written Perl script. The resulted
files were submitted for peptide/protein identification to the Mascot (v2.2, Matrix Science)
database-searching program. Parameters set during the searches were as follows: custom
protein database, a peptide mass tolerance of 2.2 u to account for higher isotopes of large
peptides and MS/MS tolerance of 0.6 Da, semi-trypsin specificity with up to two missed
cleavages. Variable modification was set to consider oxidation on methionine residues.
Sequest and Mascot results were imported into Scaffold 2.2.03 software (Proteome Software
Inc.) for analyzing with the X!Tandem search algorithm and statistical validation of peptide/
protein identities. Peptides validated by Scaffold at a confidence level of 50% and greater
were taken to calculate protein coverage. Identification of peptides at a confidence level of
less than 50% was considered positive if their corresponding m/z value from the survey
MS1 scans were found to be within 10 ppm mass tolerance.
Animals and Immunization
Animal studies were performed in accordance with regulations set forth by the Institutional
Animal Care and Use Committee and guidelines of the Association for Assessment and
Accreditation of Laboratory Animal Care. For all experiments, BALB/c mice were acquired
from the Charles River Breeding Laboratory (Wilmington, MA) and quarantined for 7 days
prior to study start. Inoculations (100 µL) were administered intramuscularly on study days
1, 14 and 28 and mice were bled via the submandibular vein on days 0, 7, 21, 35 and 49.
Weights were recorded at each time-point and monitored for indications of adverse effects
due to dosing, although none were observed. Mice were euthanized following the final bleed
on day 49.
In the first study, each group contained 10 mice (5 female and 5 male) with the exception of
the histidine buffer control group which contained only 7 mice. No significant differences
were observed in end-point titers between male and female mice. Formulations of MxiH Δ5
were dosed at 1 (M1), 10 (M10) and 50 (M50) µg/dose. The two control groups were dosed
with either formulation buffer or 0.5 mg/mL aluminum in formulation buffer.
Study 2 contained groups of 7 mice (female), and a single control group containing 5 mice
(0.5 mg/mL aluminum in 10mM isotonic His buffer). MxiH Δ5 and MxiH Needle were
dosed separately at 10 µg, both in the formulation buffer as well as adsorbed to Alhydrogel
(M-Soln, M-His, N-Soln, and N-His, respectively). The third study, conducted concurrently
with Study 2, involved groups of 8 mice (female), and a control group of 5 mice (0.5 mg/mL
aluminum in 10mM isotonic His buffer). Formulations of PrgI Δ5 were administered at 1, 10
and 50 µg/dose (P1, P10, and P50). Non-adsorbed formulations (i.e., formulations which did
not contain adjuvant) were also administered at 50 µg for PrgI Δ5 (P50-Soln).
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ELISA / IgG Detection in Serum Samples
A standard Enzyme Linked Immunosorbent Assay (ELISA) was used to evaluate the
stability of the adsorbed PrgI Δ5 vaccine. Only anti-PrgI Δ5 antibodies (polyclonal) were
available and therefore only the PrgI formulation stability was studied in this manner. In
addition, the antigen specific IgG titers for individual sera samples of MxiH Δ5, MxiH
needle, and PrgI Δ5 was determined using this assay. All solutions and incubated adsorbed
samples were plated (100 µL) onto Nunc-Immuno™ MediSorp™ (Nalge Nunc
International, Wiesbaden, Germany) 96-well plates at 10 µg/mL in carbonate buffer (pH 9.6)
overnight at 4 °C. Plates were blocked with Superblock (ThermoScientific, Rockford, IL)
per product instructions. A dilution of Anti-PrgIΔ5 IgG (1:10,000) and Sera dilutions (100
µL) were prepared in Superblock and allowed to incubate on the plate for 2 hours at RT. For
stability studies, the plates were washed 4 times using a 0.85% sodium chloride solution
while for immunogenicity analysis, the plates were washed three times using PBS
containing 0.05% Tween 20, and finally with PBS buffer alone. HRP-conjugated goat anti-
Mouse monoclonal antibody (Sigma, St. Louis, MO) was diluted 1:500 in blocking buffer,
plated (100 µL) and incubated for 1 hour at RT. The plates were then washed as above, and
3,3’5,5’-TetraMethylBenzidine (TMB) substrate (100 µL) (Sigma, St. Louis, MO) was
added. After 30 minutes at RT, 2 M HCl (100 µL) was added to quench the reaction and
plates were read using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA)
at 450 nm.
Statistical Analysis
The geometric mean was used to represent group responses, and error was determined as the
standard deviation. Statistical significance was determined with Student’s t-test using
Microsoft Excel. Significance was determined as p ≤ 0.05.
RESULTS
Screening for Excipients
A panel of Generally Regarded as Safe (GRAS) compounds was screened for potential
stabilizing effects on the secondary structure of all three recombinant proteins using
temperature dependent circular dichroism spectroscopy. As shown in Figure 1, MxiH Δ5 and
PrgI Δ5 displayed broad yet distinctly sigmoidal transitions with midpoints of thermal
melting (Tm) of 40.6 +/− 0.2 and 34.8 +/− 0.5 °C, respectively. For the purposes of excipient
selection, we used changes in Tm as a quantitative measure of potential excipient effects.
The melting curve for BsaL Δ5 did not display sigmoidal behavior and as a result no thermal
midpoint could be assigned. This difference observed in the melting curves may be
attributed to the absence of a critical salt bridge in BsaL Δ5 which is present in both
MxiH Δ5 and PrgI Δ5.19
For both MxiH Δ5 and PrgI Δ5, stabilization, as represented by an increase in Tm, was
observed in the presence of polyols and carbohydrates including glycerol, sorbitol, dextrose,
trehalose, and sucrose. As shown in Figure 2, greater stabilization was typically a function
of increasing excipient concentration. Although it was not possible to confirm with Tm
values, visual comparison of the BsaL Δ5 melting curves demonstrated similar stabilization
trends (data not shown). Combinations of excipients were also screened using circular
dichroism spectroscopy where the proteins demonstrated increased thermal stability in the
presence of the chosen excipient combinations (data not shown). Shown in Figure 3 are the
thermal melting curves for both MxiH Δ5 and PrgI Δ5 in the presence and absence of 10%
sucrose and 5% dextrose, an excipient combination which was identified as optimal for all
three proteins. In both cases, approximately 4 °C of additional thermal stabilization was
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gained in the presence of 10% sucrose and 5% dextrose (MxiH Δ5, 40.4 to 44.4 °C and
PrgI Δ5, 35.7 to 39.3 °C)
Adsorption Isotherms
The three proteins studied in this work are acidic, with iso-electric points in the region of
4.5–5. The two most commonly employed aluminum salt adjuvants are aluminum hydroxide
which is positively charged at neutral pH and has a point of zero charge (PZC) of 11, and
aluminum phosphate which is negatively charged at neutral pH and has a PZC of
approximately 5–7.24 As one would expect, minimal adsorption of the needle proteins
occurs in the presence of aluminum phosphate (data not shown), while substantial
interaction is observed with aluminum hydroxide. This phenomenon is presumably due to
the electrostatic repulsive forces present between the aluminum phosphate and the protein at
neutral pH, and the electrostatic attractive forces present between the aluminum hydroxide
and the proteins. As shown in Figure 4, the three proteins display similar adsorption
isotherms with high levels of protein loading. When the data were plotted according to the
Langmuir equation,25 straight lines with R2 values in the range of 0.984 to 0.999 were
obtained. The adsorptive capacities were calculated to be 1.56, 1.72 and 1.62 mg/mg
aluminum for PrgI Δ5, BsaL Δ5 and MxiH Δ5, respectively. The adsorption coefficients for
0.85 mg/mL aluminum were also calculated to be 119, 116 and 96 mL/mg for PrgI Δ5,
BsaL Δ5 and MxiH Δ5, respectively.
Adsorption Mechanism
To investigate the forces responsible for adsorption of the needle proteins to aluminum
hydroxide, a series of ‘elution’ solutions (Table 1) were prepared and the adsorbed samples
were treated with each. The elution solutions were expected to primarily inhibit a specific
type of protein-adjuvant interaction. Adsorbed samples were prepared as described above
and supernatants were assayed for protein content prior to treatment. In all cases, < 2%
residual protein was observed indicating that approximately 98% of the protein was
adsorbed prior to ‘elution’ treatment. As shown in Table 1, when freshly adsorbed samples
(< 24 h incubation) were treated, nearly all of the protein was desorbed from the surface in
the presence of 1.0 M guanidine hydrochloride, 1.0 M sodium citrate, 1.0 M monobasic
sodium phosphate or 1.0 M dibasic sodium phosphate. Although the proteins have highly
charged surfaces,19 they do not appear to interact with the adjuvant directly through
electrostatic interactions since they are not eluted in the presence of up to 3.0 M NaCl. If the
adjuvant-adsorbed formulations were aged prior to analysis, the results differed
significantly. After 2 weeks of incubation at 4 °C, only the sodium phosphate and sodium
citrate solutions were able to desorb the protein. In both cases, the quantity eluted
represented only approximately 75% of the total protein. At an increased incubation
temperature of 40 °C, the results were similar, but the quantity eluted was further reduced to
less than half of the original amount. These observations suggest that interactions occurring
initially upon adsorption change with time as the protein establishes new contacts with the
surface. Given the lack of elution in the presence of high salt concentrations and the strongly
hydrophilic nature of the proteins and the surface, we hypothesize that interaction with the
surface at longer times probably involves Van der Waals forces or hydrogen bonding.
Stability of Vaccine Antigens Adsorbed to Adjuvants
To examine the stability of the adsorbed product, we employed a standard ELISA method.
We were particularly interested in evaluating the effect of decreased protein desorption over
time in terms of changes in the protein as detected by interaction with a specific antibody.
We therefore compared the antibody binding of solution protein to that of adsorbed protein
that had either been stored at 4 or 40 °C for over 6 months. As shown in Figure 5, no
significant difference (p<0.0001) in interaction with antibody was observed for PrgI Δ5
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when present in solution or adsorbed on the adjuvant and stored for 6 months at 4 °C. A
second sample which had been stored at 40 °C, however, did display a significantly lower
response than both the solution material and the adsorbed material stored at 4 °C. This result
suggests loss of at least one epitope upon long-term storage at elevated temperatures.
Capillary liquid chromatography-mass spectrometry analysis and protein mapping
To further examine the difference observed by ELISA between the adsorbed PrgI Δ5
formulations stored at 4 vs. 40 °C, we eluted protein from the adjuvant surface using 1.0 M
sodium phosphate and obtained a peptide map for both samples. We also acquired a map of
the soluble parent protein which had been frozen since production. Although the coverage
was not optimal due to the presence of several small peptides, all residues commonly
associated with chemical degradation reactions were present and no changes were observed
in either of the adsorbed samples. This suggests that the decrease in antibody binding
observed in the ELISA assay was due to a change in protein conformation as opposed to
chemical modification of the amino acid sequence.
Generation of Humoral Responses
Mice were intramuscularly immunized three times at two week intervals (study days 1, 14
and 28), and blood samples were collected via the submandibular vein on days 0, 7, 21, 35,
and 49. For all cases in which significant increases in IgG were observed, the mice had
endpoint titers within two dilutions of the geometric mean. Figures displaying individual
titers for each experiment can be found in the Supplemental Data. On day 0 of the first
experiment, all mice had anti-MxiH IgG titers near 128 (Figure 6A). Mice in the control
group maintained a similar value throughout the study. Animals dosed with 1 µg of MxiH Δ5
(M1) showed only a slight increase in antibody response throughout the study (p<0.02, day
49 compared to day 0), while those administered a 10 µg dose (M10) showed some response
after the second boost compared to the control groups (p<0.0015). Mice who received the
highest dose of 50 µg (M50) displayed an increase in serum IgG following the initial dose
(p=0.0002) which continued to increase following the two booster injections. In all cases,
the responses observed following the second boost were sustained for three weeks after the
last injection.
The second and third studies followed the same immunization and blood collection schedule
as the initial experiment. In the second study, the formulation doses were 10 µg. Similar to
the initial experiment, all mice had anti-MxiH IgG endpoint titers of approximately 256 on
day 0, and the control group maintained similar values throughout the study (Figure 6B).
Those animals who received a 10 µg dose of MxiH Δ5 in formulation buffer (M-Soln) did
not show a significant response throughout the entire study. When the same dose was
administered adsorbed to Alhydrogel (M-Al), again no response was observed. A significant
anti-MxiH IgG response was observed following the initial injection and further increased
following the first booster when mice were inoculated with the polymerized form of MxiH
in solution (N-Soln.). The responses observed following the second booster increased only
slightly (p<0.05). When the same dose was administered adsorbed to the adjuvant (N-Al), a
similar trend was observed of increased magnitude.
The final study involved the needle protein PrgI Δ5 from S. typhimurium. At the start of the
study, all mice displayed PrgI specific IgG endpoint titers of approximately 64 (Figure 6C).
The control group displayed a similar value throughout the study. Mice given the 1 µg dose
of PrgI Δ5 (P1) demonstrated an increase in titer over the course of the experiment (p<0.005,
day 49 compared to day 0). The mice inoculated with 10 µg (P10) displayed an increase
following the first dose, and levels rose somewhat during the remainder of the experiment.
The mice in the highest Alhydrogel adsorbed dose group (P50), had increased titers
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following each injection, while in the absence of Alhydrogel (P50-Soln), the response was
comparable to that of P1 and P10.
DISCUSSION
As described above, previous work has thoroughly defined the solution stability of each of
the three proteins over a range of pH 3–8 and under thermal stress. We found that these
mutant proteins, which are composed of helix-turn-helix structural elements, are sensitive to
pH, are thermally labile and have reversible thermal transitions. They also display molten
globule-like behavior in the physiological temperature range which may be critical to their
transport through the growing needle structure given its limited diameter of 1.5–3.0 nm for
the pathogens studied here. In this study, we have further characterized these proposed
vaccine candidates for the purpose of formulation development. Excipient screening
indicated that their thermal stability is increased by the presence of polyols and
carbohydrates probably by the well described mechanism of preferential hydration.26
Binding isotherms for each antigen to aluminum hydroxide were also obtained. In all three
cases, data were well described by the Langmuir equation with adsorptive capacities in the
range of 1.56–1.72 mg/mg aluminum. Although the proteins may initially interact with
aluminum hydroxide through electrostatic interactions, hydrogen bonds and Van der Waals
(apolar) forces may be involved at longer incubation times. Additionally, a time-dependent
change was observed in the desorption profile of adsorbed proteins. These changes in
adsorption behavior were characterized over time using both ELISA and peptide mapping
methods for MxiH. ELISA results indicated a difference in the antibody binding ability of
the adsorbed protein stored for ~ 6 months at 40 °C while no change was observed at 4 °C.
Peptide maps of the adsorbed protein indicate that relative to the protein primary structure
prior to adsorption, no chemical changes were observed.
Upon examining the antigenic potential of the TTSS needle proteins, the MxiH monomer
was found to be weakly immunogenic and dose dependent, requiring large doses of antigen,
multiple boosts and the presence of an adjuvant to elicit a strong immune response. The
polymerized form of the needle protein, expressed without the C-terminal truncation, is
much more immunogenic than the monomeric version. There exists a well established
correlation between antigen size, multivalency and immune response.22 Thus, it is possible
that the increased immunogenicity observed here results from the increased size and epitope
valency of the polymerized needle. Although these oligomers are perhaps ideal vaccine
candidates, they need to be of defined, reproducible and stable size. Production of such
uniform and homogeneous polymerized needles is currently under investigation. The current
studies assume that excipients which stabilize the monomers will most probably be effective
in stabilizing the oligomers as well. It is also possible that the five-residue C-terminal region
which is absent in the monomeric form constitutes a potent epitope, though this is unlikely.
As with the monomeric version, the response of the polymerized form of MxiH is boosted
by adsorption to an aluminum salt adjuvant. Additionally, no adverse effects were observed
throughout the immunization regimen as indicated by normal weight gain patterns (data not
shown). In all studies where increases in specific antibody titers were observed, there were
no non-responders suggesting that the formulations may be efficacious if IgG levels are
predictive of protection. Antigens from the Salmonella system also appear to elicit
substantial immune responses. PrgI displayed dose dependent behavior, and titers increased
markedly when booster doses were administered.
While the studies presented here support further vaccine development utilizing TTSS needle
proteins, further work is clearly necessary. Additional studies will focus on tailoring the
formulation to elicit an appropriate response based on the pathogenesis of each species to
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ensure protection. The current immunogenicity studies support the development of TTSS
proteins as antigens in multivalent subunit vaccines.
Concurrent with this work, a second protein integral to the TTSS has also been developed as
a potential vaccine candidate. This protein, often referred to as the TTSS ‘tip’ protein, has
been shown in Shigella to reside at the distal tip during the initial stages of infection.27
Other groups have shown this protein from the Shigella system, IpaD, to be highly
immunogenic.28 Additionally, antibodies specific to this protein have been shown to
neutralize host-cell infection by Shigella suggesting protective behavior.27 It is interesting to
note that the excipients which provided the greatest degree of thermal stabilization for the
needle proteins were similar to those which stabilize the tip proteins (unpublished data), and
that both groups of proteins strongly adsorb to aluminum hydroxide. In the following paper,
we describe the formulation and antigenicity of representative tip proteins and their
combination with TTSS needle proteins as a next step to the creation of a general form of
gram negative bacterial vaccine.
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Circular dichroism thermal melting curves for each MxiH Δ5 ( ), PrgI Δ5 ( ) and
BsaL Δ5 ( ) at 0.2 mg/mL in isotonic 10 mM Histidine buffer at pH 6.0.
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Changes in Tm (°C) as measured by circular dichroism spectroscopy for MxiH Δ5 ( ) and
PrgI Δ5 ( ).
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Circular dichroism thermal melting curves for (A) MxiH Δ5 and (B) PrgI Δ5 at 222 nm in
the presence ( ) and absence (-) of 10% Sucrose and 5% Dextrose.
Barrett et al. Page 13














Adsorption isotherms for MxiH Δ5 (A), PrgI Δ5 (B) and BsaL Δ5 (C) with 0.5 mg/mL
aluminum in isotonic 10 mM histidine buffer at pH 6. Solid lines represent 100%
adsorption.
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Absorbance values observed at 450 nm when each sample was plated and analyzed by a
standard ELISA protocol.
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Anti MxiH (A and B) and PrgI (C) IgG serum responses following intramuscular injections
on study days 1, 14, 28 of Buffer Control ( ), Alhydrogel Control ( ), M1/M-His/P1 ( ),
M10/M-Al/P10 ( ), M50/N-His/P50 ( ). N-Al/P-Soln ( ).
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Table 1
Protein (mg/mL) present in sample supernatant as assayed by UV absorbance spectroscopy following ‘elution’
treatment. All samples originally contained 0.2 mg/mL protein in the presence of 0.5 mg/mL Aluminum.
Where a dash is present no sample was analyzed. Error was estimated at approximately 0.05 mg/mL.
MxiHΔ5 Freshly Prepared 2 wks, 4 °C 2 wks, 40 °C
Prior to Elution 0.001 0.001 0.000
10 mM Histidine 0.003 0.002 0.014
0.5 M NaCl 0.001 - -
0.75 M NaCl 0.002 - -
1.0 M NaCl 0.002 - -
2.0 NaCl 0.005 - -
3.0 M NaCl 0.001 0.000 -
1.0 M Gdn HCl 0.003 0.003 0.001
1.0 M NaCit 0.143 0.091 0.039
1.0 M NaPhos 0.201 0.160 0.078
70 mM SDS 0.088 - -
PrgIΔ5
Prior to Elution 0.001 0.002 0.002
10 mM Histidine 0.003 0.003 0.000
0.5 M NaCl 0.001 - -
0.75 M NaCl 0.002 - -
1.0 M NaCl 0.004 - -
2.0 NaCl 0.003 - -
3.0 M NaCl 0.000 0.006 -
1.0 M Gdn HCl 0.005 0.006 0.004
1.0 M NaCit 0.137 0.081 0.036
1.0 M NaPhos 0.197 0.151 0.092
70 mM SDS 0.056 - -
BsaLΔ5
Prior to Elution 0.001 0.002 0.002
10 mM Histidine 0.004 0.003 0.003
0.5 M NaCl 0.000 - -
0.75 M NaCl 0.001 - -
1.0 M NaCl 0.006 - -
2.0 NaCl 0.003 - -
3.0 M NaCl 0.000 0.000 -
1.0 M Gdn HCl 0.002 0.005 0.002
1.0 M NaCit 0.171 0.105 0.036
1.0 M NaPhos 0.196 0.154 0.082
70 mM SDS 0.100 - -
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